These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 24076314)

  • 1. Advances in cellular reprogramming: moving toward a reprieve from immunogenicity.
    Gallegos TF; Sancho-Martinez I; Izpisua Belmonte JC
    Immunol Lett; 2013; 155(1-2):14-7. PubMed ID: 24076314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Can controlled cellular reprogramming be achieved using microRNAs?
    Sun X; Fu X; Han W; Zhao Y; Liu H
    Ageing Res Rev; 2010 Oct; 9(4):475-83. PubMed ID: 20601195
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progress made in the reprogramming field: new factors, new strategies and a new outlook.
    Hussein SM; Nagy AA
    Curr Opin Genet Dev; 2012 Oct; 22(5):435-43. PubMed ID: 22959308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulation of human allogeneic and syngeneic pluripotent stem cells and immunological implications for transplantation.
    Sackett SD; Brown ME; Tremmel DM; Ellis T; Burlingham WJ; Odorico JS
    Transplant Rev (Orlando); 2016 Apr; 30(2):61-70. PubMed ID: 26970668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Application of iPSC technology to cancer treatment].
    Oshima N; Aoi T
    Gan To Kagaku Ryoho; 2015 Feb; 42(2):139-43. PubMed ID: 25743131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reprogramming of somatic cells.
    Rajasingh J
    Prog Mol Biol Transl Sci; 2012; 111():51-82. PubMed ID: 22917226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Artificial reprogramming of human somatic cells to generate pluripotent stem cells: a possible alternative to the controversial use of human embryonic stem cells.
    Romano G
    Drug News Perspect; 2008 Oct; 21(8):440-5. PubMed ID: 19034350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploiting pluripotency for therapeutic gain.
    Deng W
    Panminerva Med; 2010 Jun; 52(2):167-73. PubMed ID: 20517198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evolution of induced pluripotent stem cell technology.
    Zhou H; Ding S
    Curr Opin Hematol; 2010 Jul; 17(4):276-80. PubMed ID: 20442654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is aging a barrier to reprogramming? Lessons from induced pluripotent stem cells.
    Phanthong P; Raveh-Amit H; Li T; Kitiyanant Y; Dinnyes A
    Biogerontology; 2013 Dec; 14(6):591-602. PubMed ID: 23963527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in cell lineage reprogramming.
    Zhou J; Yue W; Pei X
    Sci China Life Sci; 2013 Mar; 56(3):228-33. PubMed ID: 23526388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of reprogramming efficiency between transduction of reprogramming factors, cell-cell fusion, and cytoplast fusion.
    Hasegawa K; Zhang P; Wei Z; Pomeroy JE; Lu W; Pera MF
    Stem Cells; 2010 Aug; 28(8):1338-48. PubMed ID: 20572011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A promising approach to iPSC-based cell therapy for diabetic wound treatment: direct lineage reprogramming.
    Li S; Li Q
    Mol Cell Endocrinol; 2014 Aug; 393(1-2):8-15. PubMed ID: 24911883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cell reprogramming: expectations and challenges for chemistry in stem cell biology and regenerative medicine.
    Anastasia L; Pelissero G; Venerando B; Tettamanti G
    Cell Death Differ; 2010 Aug; 17(8):1230-7. PubMed ID: 20168332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Embryonic stem cell extracts: use in differentiation and reprogramming.
    Han J; Sidhu K
    Regen Med; 2011 Mar; 6(2):215-27. PubMed ID: 21391855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induced human pluripotent stem cells and advanced therapies: future perspectives for the treatment of haemophilia?
    Liras A
    Thromb Res; 2011 Jul; 128(1):8-13. PubMed ID: 21396685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cellular reprogramming to reset epigenetic signatures.
    Hewitt KJ; Garlick JA
    Mol Aspects Med; 2013; 34(4):841-8. PubMed ID: 22982217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Malignant germ cell-like tumors, expressing Ki-1 antigen (CD30), are revealed during in vivo differentiation of partially reprogrammed human-induced pluripotent stem cells.
    Griscelli F; Féraud O; Oudrhiri N; Gobbo E; Casal I; Chomel JC; Biéche I; Duvillard P; Opolon P; Turhan AG; Bennaceur-Griscelli A
    Am J Pathol; 2012 May; 180(5):2084-96. PubMed ID: 22425713
    [TBL] [Abstract][Full Text] [Related]  

  • 19. "Mouse Clone Model" for evaluating the immunogenicity and tumorigenicity of pluripotent stem cells.
    Zhang G; Zhang Y
    Stem Cell Res Ther; 2015 Dec; 6():255. PubMed ID: 26687081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stem Cell Therapy and Immunological Rejection in Animal Models.
    Jin X; Lin T; Xu Y
    Curr Mol Pharmacol; 2016; 9(4):284-288. PubMed ID: 26415913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.